Author

Michael Grimm

A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF A NOVEL RECOMBINANT, HUMANISED, ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY (RPC4046) IN PATIENTS WITH ACTIVE EOSINOPHILIC OESOPHAGITIS: RESULTS OF THE HEROES STUDY

Ikuo Hirano, Margaret H. Collins, Yudith Assouline-Dayan, Larry Evans, Sandeep Gupta, Alain Schoepfer, Michael Grimm, Heather Smith, Cindy-ann Tompkins, Amy Woo, Robert Peach, Paul A. Frohna, Sheila Gujrathi, Richard Aranda, Evan S Dellon

MARKERS OF ESOPHAGEAL EPITHELIAL-MESENCHYMAL TRANSITION ARE SIGNIFICANTLY REDUCED IN ACTIVE EOSINOPHILIC ESOPHAGITIS FOLLOWING 16 WEEKS OF TREATMENT WITH RPC4046, AN ANTI-INTERLEUKIN-13 MONOCLONAL ANTIBODY

Peter Gann, Ryan Deaton, Nathan McMahon, Margaret H. Collins, Evan S Dellon, Ikuo Hirano, Michael Grimm, Amy Woo, Mahinda Karunaratne, Allan Olson, Richard Aranda, Gregory J. Opiteck

Item 1 - 2 / 2
1